After Medarex buy, biotech investors ask who’s next

NEW YORK (Reuters) – Investors bid up shares of Regeneron Pharmaceuticals Inc and Seattle Genetics Inc on Thursday after Medarex Inc agreed to be acquired by Bristol-Myers Squibb Co at a 90 percent premium.

Leave a Reply